LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Eli Lilly (LLY) and partner Incyte (INCY) announced that a late-stage study evaluating oral baricitinib in adolescent patients (aged 12-18) with severe alopecia areata (AA) showed clinically meaningful improvements in hair regrowth on the scalp, eyebrows and eyelashes at Week 36.The phase III BRAVE-AA-PEDS study enrolled 257 patients who were randomized to receive either a dose of baricitinib (4 mg or 2 mg) or placebo. AA is an immune system disorder that leads to patchy hair loss on the scalp, face, and oc ...